November 26, 2021 08:35 AM ESTUpdated February 1, 01:33 AM
Bioregnum
Cell/Gene Tx

What were End­points read­ers tun­ing in­to this year? Here’s a look at our 15 most pop­u­lar re­ports of the year (so far)

John Carroll

Editor & Founder

At the be­gin­ning of this year, I laid out a ba­sic ob­jec­tive for End­points News as we head­ed to our 5th an­niver­sary. We’ve long been …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

Bio­Marin makes Phase 3 buy, pay­ing $270M for rare dis­ease out­fit In­ozyme

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times